Jonathan D.J. Loeb, Ph.D.'s practice focuses on life sciences litigation and strategic patent counseling. To achieve his clients' strategic goals, Dr. Loeb melds the technical expertise gained in more than 10 years as a bench scientist and teacher with his deep experience in all aspects of high-stakes biotech, pharmaceutical, and medical device patent litigation.
Dr. Loeb has represented clients before U.S. District Courts, the International Trade Commission, and the Federal Circuit Court of Appeals. Dr. Loeb also represents clients in reexamination proceedings before the U.S. Patent Office and has provided advice in patent revocation and infringement actions in various foreign jurisdictions.
Before attending Stanford Law School, Dr. Loeb obtained his Ph.D. in Biology from the Massachusetts Institute of Technology. At M.I.T., Dr. Loeb worked at the Whitehead Institute for Biomedical Research with its then director, Professor Gerald R. Fink. Dr. Loeb's doctoral research concerned the genetics and cell biology of the Nuclear Pore Complex in Saccharomyces cerevisiae. After receiving his Ph.D., Dr. Loeb did post-doctoral research at M.I.T. and the University of California, Irvine, focusing on the pathogenesis of fungi that afflict immunocompromised individuals. Dr. Loeb is experienced in many biotechnologies, from molecular genetics, biochemistry, fluorescent proteins, and microscopy. Dr. Loeb is lead author of a number of scientific papers in peer-reviewed biology journals.
Dr. Loeb is routinely named a "Life Sciences Star" by LMG Life Sciences. In 2019 and 2020, Dr. Loeb was named an Outstanding Volunteer for work for the Justice & Diversity Center of the Bar Association of San Francisco (JDC). Dr. Loeb was recognized by The Legal 500 US for Patent Litigation in 2020.
- Novartis v. Eli Lilly (N.D. Cal., E.D. Va., 4th Cir., 9th Cir., and ex-U.S.). Represented Eli Lilly & Co. in global litigations, serving as U.S. counsel in 28 U.S.C. § 1782 discovery actions for use in foreign proceedings, and strategic co-counsel in multiple European litigations and European Patent Office proceedings that arose from the sale of a patent portfolio from Genentech, Inc. to Novartis Pharma AG. In October 2022, Novartis and Lilly entered into a global settlement agreement that concluded the dispute between the parties.
- Par Pharmaceutical, Inc. v. Amneal EU Ltd., et al. (D. Del.). Trial counsel representing Par in a Hatch-Waxman patent infringement case regarding Par’s VASOSTRICT® (vasopressin) product against multiple generic pharmaceutical manufacturers.
- Cedars-Sinai Medical Center v. Quest Diagnostics, Inc. (C.D. Cal.). Served as lead counsel for Defendant Quest Diagnostics accused of patent infringement, trade secret misappropriation, and breach of contract. Obtained summary judgment of invalidity and jury verdict of no misappropriation or breach.
- Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (D. Del.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo's OPANA® ER (oxymorphone ER) controlled release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity.
- Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (S.D.N.Y.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo's OPANA® ER (oxymorphone ER) controlled-release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity.
- Endo Pharmaceuticals Inc. vs. Watson Pharmaceuticals, Inc., et al. (S.D.N.Y.). Trial counsel representing Endo in a Hatch-Waxman patent infringement case regarding Endo's LIDODERM® (lidocaine) patch product against generic pharmaceutical manufacturers. Settled favorably after trial.
- Amgen Inc. v. F. Hoffman LaRoche, Ltd. (D. Mass.). Served as a member of the Senior Trial Team representing Amgen in a patent infringement case regarding recombinant erythropoietin. Obtained a jury verdict of infringement and validity.
- In the Matter of Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoietin (USITC). Trial counsel for Amgen in ITC investigation regarding the exclusion from importation into the U.S. of Roche's MIRCERA® (methoxy polyethylene glycol-epoetin beta) product (appeal in Amgen's favor, settled favorably).
- Pfizer Inc v. Lilly ICOS (D. Del.). Defended Lilly ICOS in a patent dispute regarding phosphodiesterase-5 inhibitors CIALIS® (tadalafil) and VIAGRA® (sildenafil citrate). Obtained stay after successful petition for reexamination.
- Boston Scientific v. Cook (C.D. Ill. and 7th Cir.). Counsel for Angiotech in dispute between licensees regarding license rights to paclitaxel stents (favorably resolved).
- Amgen Inc. v. Hoechst Marion Roussel, Inc. (D. Mass.). Represented Amgen in this patent dispute, obtaining holdings of infringement and validity in two bench trials as well as numerous appeals.
- Biogen v. Amgen (D. Mass.). Represented Amgen in infringement action involving Amgen's recombinant granulocyte colony stimulating factor product NEUPOGEN® (filgrastim). Summary judgment in Amgen's favor.
- Biologics Makers Have a Patent Protector in US Discovery Statute - Bloomberg Law (June 7, 2024)
-
- University of California, Berkeley, A.B., Molecular Biology, 1987, High Honors, recipient of the Departmental Citation (awarded to top student in department), National Merit Scholar
- Massachusetts Institute of Technology (MIT), Ph.D., Biology, 1995
- Stanford Law School, J.D., 2000
-
- California
- United States Court of Appeals for the Federal Circuit
- United States Patent and Trademark Office
- United States District Court for the Northern District of California